Filters
Publications
Displayed are Syndax Sponsored Studies. Search results may include information that is not consistent with the product's Full Prescribing Information. Syndax does not recommend uses that are inconsistent with the Full Prescribing Information.
American Society of Hematology
(Revumenib) The Menin Inhibitor Revumenib (SNDX-5613) Leads to Durable Responses in Patients with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase 1 Study
2022
American Society of Hematology
(Revumenib) Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) Leukemia Patients Achieving Remissions after Menin Inhibition: Revumenib (SNDX-5613) Ph1 Experience
2022
American Association for Cancer Research
(Revumenib) Characterization of Acquired Resistance Mutations to Menin Inhibitors
2023
Nature
(Revumenib) MEN1 Mutations Mediate Clinical Resistance to Menin Inhibition
2023
Nature
(Revumenib) The Menin Inhibitor Revumenib in KMT2A-rearranged or NPM1-mutant Leukaemia
2023
Blood Cancer Journal
(Revumenib) Targeting of Epigenetic Co-dependencies Enhances Anti-AML Efficacy of Menin Inhibitor in AML With MLL1-r or Mutant NPM1
2023
American Society of Pediatric Hematology/Oncology
(Revumenib) Menin Inhibition in Pediatric KMT2Ar Leukemia: Phase 1 and Expanded Access Experience With Revumenib
2023
European Hematology Association
(Revumenib) Revumenib in Patients With Acute Leukemias: Compassionate Use Program Experience
2023
American Society of Hematology
(Revumenib) Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
2023
American Society of Hematology
(Revumenib) Revumenib Maintenance Therapy Following Revumenib-Induced Remission and Transplant
2023